Researchers track Long-Term risks after experimental cancer therapy
NCT ID NCT05017662
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study followed 20 people with neuroendocrine tumors who had already received the experimental drug 177Lu-IPN01072 in an earlier trial. The goal was to check for long-term side effects, such as new cancers. No new treatment was given; participants were simply monitored over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Hôtel Dieu de Nantes
Nantes, 44093 Cedex 1, France
-
Medical University of Vienna
Vienna, 1090, Austria
-
Peter Maccallum Cancer Center
Melbourne, 3002, Australia
-
Ramsay Hollywood Private Hospital
Perth, 6009, Australia
-
Royal Free Hospital London
London, NW3 2QG, United Kingdom
-
University Hospital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.